Active — Not RecruitingNot Applicable

Biomarkers and Choroidal Neovascularization

France250 participantsStarted 2020-07-06

Plain-language summary

The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patients of group 1: * Patients with type 1 choroidal neovascularization in a context of central serous chorioretinoathy or age related macular degeneration * Patients without intravitreal injection or last intravitreal injection \> 3 months * Informed signed consent Patients of group 2: * Patients without choroidal neovascularization * Patients with intraocular surgery (cataract or vitrectomy surgery) * Signed consent Exclusion Criteria: * Myocardial infarction \< 12 months * Chronic renal failure * Inflammatory disease * Infectious disease :HIV, viral hepatitis, tuberculosis * Type 1 or 2 Diabetes * Patients treated by mineralocorticoid antagonist treatment. * Type 2 or 3 choroidal neovascularization * Pregnant woman

What they're measuring

biomarker analysis in blood and aqueous humor of patients with neovascularization and controls

Timeframe: 24 months

biomarker analysis in blood and aqueous humor of patients with neovascularization and controls

Timeframe: 24 months

Trial details

NCT IDNCT04439708

SponsorInstitut National de la Santé Et de la Recherche Médicale, France

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2027-01-06

View on ClinicalTrials.gov More Choroidal Neovascularization trials